Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi).
Tarella C, Zanni M, Di Nicola M, Patti C, Calvi R, Pescarollo A, Zoli V, Fornari A, Novero D, Cabras A, Stella M, Comino A, Remotti D, Ponzoni M, Caracciolo D, Ladetto M, Magni M, Devizzi L, Rosato R, Boccadoro M, Bregni M, Corradini P, Gallamini A, Majolino I, Mirto S, Gianni AM; Gruppo Italiano Terapie Innovative nei Linfomi.
Tarella C, et al. Among authors: corradini p.
Leukemia. 2007 Aug;21(8):1802-11. doi: 10.1038/sj.leu.2404781. Epub 2007 Jun 7.
Leukemia. 2007.
PMID: 17554382